Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Urolithin A and Its Effects on Attention and Sleep Timing in Healthcare Workers After Night Shifts

13 novembre 2026 mis à jour par: Liangkai Chen

Effects of Urolithin A on Attention and Circadian Rhythm of Sleep in Healthcare Workers After Night Shifts: An Interventional Study

This pilot study will examine whether taking urolithin A helps healthcare workers stay focused after a night shift. It will also look at changes in fatigue, sleepiness, sleep patterns, and the body's internal clock.

The study plans to enroll 40 physicians and nurses aged 24 to 55 who work scheduled night shifts at Henan Provincial People's Hospital. Participants will be assigned by chance, in equal numbers, to take either 1 gram of urolithin A or a matching placebo capsule by mouth once each morning for five consecutive days, starting the day before the night shift. Participants and the study staff who give out the capsules or assess outcomes will not know which group each participant is in. Participants will follow their usual work schedules.

The main measure is the Stroop interference effect, which is the difference in average response time between correct answers when a color word conflicts with its displayed color and correct answers when they match. The researchers will compare how this measure changes from two days before the night shift to the scheduled follow-up assessments in the two groups.

Participants will also rate their fatigue and sleepiness, wear a wrist device to track sleep, keep a sleep diary, and provide saliva samples to measure melatonin. They will complete tasks that measure alertness and the ability to withhold a response during three MRI scans scheduled before the night shift, on the morning the shift ends, and during recovery. The study will help estimate how much the main measure varies among participants to inform a larger trial.

Aperçu de l'étude

Description détaillée

This single-center, randomized, double-blind, placebo-controlled pilot trial will be conducted at Henan Provincial People's Hospital. After providing written informed consent and completing baseline assessments, participants will be randomly assigned to a study group. An independent team member who is not involved in recruitment, intervention delivery, or outcome assessment will generate the allocation sequence using SAS version 9.4. Coded study products will be dispensed in enrollment order. Group assignments will be kept confidential until the database is locked, except when emergency unblinding is needed for participant safety.

The day on which the scheduled night shift begins is designated Day 0. Baseline assessments will take place on Day -2. Participants will take their assigned study product each morning from Day -1 through Day 3 and will work their usual scheduled night shift. Computerized Stroop testing will be conducted each morning from Day -2 through Day 4 between 07:00 and 09:00. The final assessment will take place on Day 4, after the dosing period has ended.

Task-based functional MRI will be performed at baseline (Day -2), on the morning the night shift ends (Day 1), and during recovery (Day 3). During each scan, participants will complete an 8-minute Psychomotor Vigilance Task and a 6-minute Go/No-Go task. Stimulus timing and button responses will be recorded and synchronized with image acquisition. Wrist activity recordings will be reviewed alongside sleep diaries to distinguish nighttime sleep from daytime naps and identify periods when the device was removed. Saliva will be collected at scheduled times throughout the observation period, with an additional sample at 03:00 during the night shift. Study staff will record actual sample collection times, review dosing and visit records, and document missed doses, concomitant medication use, and adverse events.

Repeated Stroop interference measurements will be analyzed using a linear mixed-effects model with terms for study group, visit, and their interaction, with adjustment for baseline performance and a participant-level random effect. Estimated between-group differences will be reported with 95% confidence intervals. Exploratory analyses will examine whether changes in task-related brain activity are associated with changes in cognitive performance, fatigue, sleepiness, sleep patterns, and salivary melatonin. Visit completion and adherence data will be used to assess the feasibility of the study procedures for a larger trial.

Type d'étude

Interventionnel

Inscription (Estimé)

40

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: Haoxiang Xu
  • Numéro de téléphone: 0371-65580020
  • E-mail: xhx0227@163.com

Lieux d'étude

    • Henan
      • Zhengzhou, Henan, Chine, 450003
        • Henan Provincial People's Hospital
        • Contact:
        • Contact:
          • Liangkai Chen, PhD
          • Numéro de téléphone: 0371-65580020
          • E-mail: clk@hust.edu.cn
        • Sous-enquêteur:
          • Haoxiang Xu, Currently pursuing a master's

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

24 ans à 55 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Aged 24 to 55 years, inclusive.
  • Physicians or nurses who work scheduled night shifts.
  • No history of neurological or psychiatric disorders.
  • No diagnosed sleep disorder.
  • No contraindications to magnetic resonance imaging (MRI).
  • Right-handed.

Exclusion Criteria:

  • Recent use of sleep aids or psychoactive medications.
  • Severe sleep disruption outside periods of shift work.
  • Gastrointestinal disease that may affect urolithin A absorption.
  • Pregnancy or breastfeeding.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Urolithin A

Participants will take 1 g of urolithin A(StanYouth™️ Urolithin A) in capsule form by mouth once daily between 07:00 and 09:00 for five consecutive days, from the day before the scheduled night shift (Day -1) through Day 3.

Oral urolithin A(StanYouth™️ Urolithin A) capsules at a total daily dose of 1 g. The capsules are taken once each morning between 07:00 and 09:00 for five consecutive days, beginning the day before the scheduled night shift (Day -1) and continuing through Day 3.

Comparateur placebo: Matching Placebo

Participants will take 1 g of matching placebo capsules by mouth once daily between 07:00 and 09:00 for five consecutive days, from Day -1 through Day 3. The placebo capsules contain no urolithin A and match the urolithin A capsules in appearance, color, and packaging.

Oral placebo capsules containing no urolithin A and matching the urolithin A capsules in appearance, color, and packaging. The capsules are taken at a total daily dose of 1 g, once each morning between 07:00 and 09:00 for five consecutive days, from Day -1 through Day 3.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change From Baseline in the Stroop Reaction Time Interference Effect
Délai: Baseline (Day -2) and follow-up on Days -1, 0, 1, 2, 3, and 4. Day 0 is the day the scheduled night shift begins.

At each assessment, the Stroop reaction time interference effect is calculated by subtracting the mean reaction time for valid correct responses in congruent trials from the mean reaction time for valid correct responses in incongruent trials. Reaction times are measured in milliseconds. Change from baseline is calculated as the interference effect at each follow-up assessment minus the baseline interference effect. A positive change indicates greater interference than at baseline.

Baseline (Day -2) and follow-up on Days -1, 0, 1, 2, 3, and 4. Day 0 is the day the scheduled night shift begins.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Stroop Reaction Time by Trial Condition,Stroop Response Accuracy by Trial Condition
Délai: Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4

Mean reaction time, in milliseconds, for valid correct responses on the computerized Stroop task, reported separately for congruent and incongruent trials.

Percentage of trials with a correct response on the computerized Stroop task, reported separately for congruent and incongruent trials.

Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4
Psychomotor Vigilance Task
Délai: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Mean reaction time, in milliseconds, for valid responses. Premature responses and omissions are excluded.

Number of responses with a reaction time of at least 500 milliseconds within the 10-second response window.

Number of slow responses divided by [prespecified denominator], multiplied by 100.

Number of presented targets for which no response is recorded within 10 seconds.

Number of omitted responses divided by[ prespecified denominator], multiplied by 100.

Number of premature responses, defined as button presses during the waiting interval or responses occurring less than 100 milliseconds after target onset.

Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
Go/No-Go Trial
Délai: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Mean reaction time, in milliseconds, for correct responses on Go trials. Percentage of presented Go trials with a valid button press within the response window.

Percentage of presented Go trials without a valid button press within the response window.

Percentage of presented No-Go trials with a button press within the response window.

Percentage of presented No-Go trials without a button press within the response window.

Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
Visual Analog Scale for Fatigue Score
Délai: Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.

Participants rate their current fatigue on a 100-mm visual analog scale. Scores range from 0 mm (no fatigue) to 100 mm (extreme fatigue), with higher scores indicating greater fatigue.

Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
Karolinska Sleepiness Scale Score
Délai: Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.

Self-rated sleepiness measured on the 9-point Karolinska Sleepiness Scale. Scores range from 1 to 9, with higher scores indicating greater sleepiness.

Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
Fatigue Severity Scale Score
Délai: Baseline (Day -2) and final follow-up (Day 4).

The 9-item Fatigue Severity Scale assesses the impact of fatigue on daily functioning over the past week. Each item is scored from 1 to 7. Item scores are summed to give a total score ranging from 9 to 63, with higher scores indicating a greater impact of fatigue.

Baseline (Day -2) and final follow-up (Day 4).
Salivary Melatonin Concentration
Délai: From 07:00 on Day -2 through the final visit on Day 4. Routine collection times are 07:00, 11:00, 15:00, 19:00, and 23:00, with an additional sample at 03:00 on Day 1.

Melatonin concentration measured in saliva samples collected at scheduled times and reported in [laboratory reporting unit].

From 07:00 on Day -2 through the final visit on Day 4. Routine collection times are 07:00, 11:00, 15:00, 19:00, and 23:00, with an additional sample at 03:00 on Day 1.
Actigraphy-Derived Sleep Parameters
Délai: Continuous monitoring from baseline (Day -2) through final follow-up (Day 4).

Total time spent asleep during the recorded sleep episode, estimated from wrist actigraphy and reported in minutes.

Percentage of time in bed spent asleep, estimated from wrist actigraphy. Time from attempting to fall asleep to estimated sleep onset, reported in minutes.

Total time spent awake after initial sleep onset and before final awakening, estimated from wrist actigraphy and reported in minutes.

Number of awakenings detected by wrist actigraphy after initial sleep onset and before final awakening.

Continuous monitoring from baseline (Day -2) through final follow-up (Day 4).
Task-Evoked Brain Activation During the Psychomotor Vigilance Task
Délai: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Task-evoked brain activation during the Psychomotor Vigilance Task will be quantified using [metric and unit] for [task contrast] in [prespecified regions or whole-brain analysis].

Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
Task-Evoked Brain Activation During the Go/No-Go Task
Délai: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Task-evoked brain activation during the Go/No-Go task will be quantified using [metric and unit] for [task contrast] in [prespecified regions or whole-brain analysis].

Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Jie Wang, PhD, Henan Provincial People's Hospital
  • Directeur d'études: Liangkai Chen, PhD, Huazhong University of Science and Technology
  • Directeur d'études: Yongli Li, PhD, Henan Provincial People's Hospital
  • Directeur d'études: Zhengqian Li, PhD, Peking University Third Hospital
  • Chercheur principal: Haoxiang Xu, Currently pursuing a master's, Henan Provincial People's Hospital

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

16 novembre 2026

Achèvement primaire (Estimé)

1 février 2027

Achèvement de l'étude (Estimé)

1 février 2027

Dates d'inscription aux études

Première soumission

13 novembre 2026

Première soumission répondant aux critères de contrôle qualité

13 novembre 2026

Première publication (Réel)

19 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 2026-150

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Description du régime IPD

The scope, timing, and access procedures for sharing individual participant data are under consideration. Any future sharing would be limited to de-identified data made available to qualified researchers or research institutions for scientific purposes, subject to ethics committee requirements and applicable regulations.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner